Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
Donghwa Kim, Duc‐Hiep Bach, Yanhua Fan, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 5
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Anticancer drug resistance: An update and perspective
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Drug Resistance Updates (2021) Vol. 59, pp. 100796-100796
Open Access | Times Cited: 259
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
Jingyi He, Zhengrong Huang, Linzhi Han, et al.
International Journal of Oncology (2021) Vol. 59, Iss. 5
Open Access | Times Cited: 212
Emerging role of tumor cell plasticity in modifying therapeutic response
Siyuan Qin, Jingwen Jiang, Yi Lü, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 198
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Xiaojing Du, Biwei Yang, Quanlin An, et al.
The Innovation (2021) Vol. 2, Iss. 2, pp. 100103-100103
Open Access | Times Cited: 117
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Kunyu Shi, Guan Wang, Junping Pei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 107
AXL signaling in cancer: from molecular insights to targeted therapies
Monika Yadav, Anuj K. Sharma, Ketki Patne, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment inEGFR-Mutated Non–Small Cell Lung Cancer
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 9, pp. 2244-2256
Open Access | Times Cited: 97
Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses
Cao Dai Phung, Tung Thanh Pham, Hanh Thuy Nguyen, et al.
Acta Biomaterialia (2020) Vol. 115, pp. 371-382
Closed Access | Times Cited: 92
Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells
Xiaoying Hou, Cong Du, Ligong Lu, et al.
World Journal of Surgical Oncology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 43
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Anna Adam‐Artigues, Enrique J. Arenas, Alex Martínez-Sabadell, et al.
Science Advances (2022) Vol. 8, Iss. 20
Open Access | Times Cited: 40
Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
Sushanta Halder, Soumi Basu, Shobhit P. Lall, et al.
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 4-5, pp. 305-324
Open Access | Times Cited: 40
Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
Tianyao Lei, Tianwei Xu, Niu Zhang, et al.
Pharmacological Research (2023) Vol. 188, pp. 106668-106668
Open Access | Times Cited: 34
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
AXL as a Target in Breast Cancer Therapy
Sierra A. Colavito
Journal of Oncology (2020) Vol. 2020, pp. 1-15
Open Access | Times Cited: 61
Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer
Patricia L. Theard, Erin Sheffels, Nancy E. Sealover, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 54
Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer
Mai Tanaka, Dietmar W. Siemann
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9953-9953
Open Access | Times Cited: 49
Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
Aliki Ntzifa, Αreti Strati, Galatea Kallergi, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 47
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
Yun Beom Sang, Joo-Hang Kim, Chang-Gon Kim, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 31
Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer
Rui Han, Conghua Lu, Chen Hu, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 6, pp. 1264-1275
Closed Access | Times Cited: 8
SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status
Brianna R. Daley, Heidi M. Vieira, Chaitra Rao, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 47
Open Access | Times Cited: 14
Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer
Simona Pellecchia, Melania Franchini, Gaetano Viscido, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 6
Mertk: An emerging target in cancer biology and immuno-oncology
Kevin C. Lahey, Varsha Gadiyar, Amanda A. Hill, et al.
International review of cell and molecular biology (2022), pp. 35-59
Open Access | Times Cited: 22
Yuanhuacin and Related Anti-Inflammatory and Anticancer Daphnane Diterpenes from Genkwa Flos—An Overview
Christian Bailly
Biomolecules (2022) Vol. 12, Iss. 2, pp. 192-192
Open Access | Times Cited: 21
6-Shogaol Overcomes Gefitinib Resistance via ER Stress in Ovarian Cancer Cells
Tae Woo Kim, Hee Gu Lee
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2639-2639
Open Access | Times Cited: 12
Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
Junnan Li, Hang Fai Kwok
Cancers (2020) Vol. 12, Iss. 6, pp. 1587-1587
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top